A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver(The Netherlands Cancer Institute), René Bernards(The Netherlands Cancer Institute), Chris Roberts(Birmingham City University), Douwe E. Atsma(The Netherlands Cancer Institute), Annuska M. Glas(Leiden University Medical Center), Stephen Friend(University of Oxford), Matthew J. Marton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tony van der Velde(Dutch Cancer Society), Dorien W. Voskuil(The Netherlands Cancer Institute), Anke Witteveen(The Netherlands Cancer Institute), Mark L Parrish(Rosetta Stone (United States)), Yudong D. He(Rosetta Stone (United States)), Hongyue Dai(Rosetta Stone (United States)), Leonie Delahaye(The Netherlands Cancer Institute), Johannes L. Peterse(The Netherlands Cancer Institute), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Harry Bartelink(Radboud University Nijmegen), Laura van ‘t Veer, Augustinus A. M. Hart(The Netherlands Cancer Institute), George J. Schreiber(Rosetta Stone (United States))
Cited by 6,519
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial
|Journal of Clinical Oncology|2007|1k
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
|New England Journal of Medicine|2015|1k
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
|New England Journal of Medicine|2001|950